



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 27 Sep 2021 (#31)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notices of Special Interest

- [NOT-AR-22-007](#) Notice of Special Interest (NOSI): Promoting Pain Research Within the NIAMS Mission Areas. The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in receiving grant applications focused on pain within the NIAMS mission areas. Many of the diseases and conditions covered by the NIAMS mission areas cause pain, disability, or disfigurement. Some of these diseases and conditions are very common, while some are rare, affecting only a few thousand people worldwide. Pain, both acute and chronic, is one of the most important symptoms affecting mobility and quality of life for patients. Yet, the mechanisms of pain, and measures and treatment options that can prevent and alleviate pain caused by these diseases are not clearly understood and remain a critical knowledge gap within the NIAMS mission. This notice applies to due dates on or after November 5, 2021 and subsequent receipt dates through January 10, 2023.

Funding Opportunity Announcements (FOA)

1. Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-329](#)

Type: R01

Application Due Date: February 05, 2022; June 05, 2022; October 05, 2022 through to Oct 2024. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and/or clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on 1) mechanistic studies with translational endpoints; and/or 2) longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported

outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-035](#)

Type: R01

Application Due Date: February 05, 2022; June 05, 2022; October 05, 2022 through to Oct 2024. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts. This FOA uses the R01 grant mechanism, while the companion FOA (PAR-22-036) uses the R21 mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-036](#)

Type: R21

Application Due Date: February 16, 2022; June 16, 2022; October 16, 2022 through to Oct 2024. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts. This FOA uses the R21 mechanism, while the companion FOA (PAR-22-035) uses the R01 grant mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.

Budget: The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

4. Effectiveness and Implementation Research for Post-Acute Interventions to Optimize Long-Term Mental Health Outcomes in Low- and Middle-Income Countries (R34 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-MH-22-100](#)

Type: R34

Application Due Date: December 09, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) seeks research applications for effectiveness and implementation science on the post-acute (long-term or chronic) management of mental health conditions. This FOA aims to advance the development of novel and innovative implementation research to improve the availability and accessibility of post-acute services in low- and middle-income countries (LMICs). All successful applications are expected to provide approaches to obtain new information concerning the different health system arrangements and using this information to identify modifiable restrictions in the supply of these services and potential policy interventions to alter the status quo.

Budget: NIMH intends to commit \$2,500,000 in FY 2022 to fund up to 7 awards. Direct costs are limited to \$450,000 over the R34 project period, with no more than \$225,000 in direct costs allowed in any single year. The total project period for an application submitted in response to this funding opportunity may not exceed 3 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105